Skip to main content

Advertisement

SpringerLink
Log in

Prognostic impacts of serum levels of C-reactive protein, albumin, and total cholesterol in patients with myelodysplastic syndromes

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Various systems for predicting the prognosis of patients with myelodysplastic syndromes (MDS) have been developed. However, associations between performance status (PS) and prognosis of MDS require further investigation. To objectively assess the impact of PS on survival, we examined laboratory findings associated with PS, including serum levels of C-reactive protein (CRP), albumin (ALB), and total cholesterol (CHOL). Patients (n = 123; male 86, female 37; median age 74 yrs.) diagnosed with MDS or myelodysplastic/myeloproliferative neoplasms at Kanazawa Medical University Hospital between 2010 and 2020 were enrolled and grouped by cutoff values determined by receiver operating characteristic analysis: 0.44 mg/dL for CRP, 4.0 g/dL for ALB, and 120 mg/dL for CHOL. The median follow-up period was 17.6 months. Kaplan–Meier analysis revealed that overall survival (OS) in the high CRP, low ALB, and low CHOL groups was significantly shorter than in the low CRP, high ALB, and high CHOL groups, respectively. Multivariable analysis revealed that elevated serum CRP was an independent prognostic risk factor independent of gender, bone marrow blast percentage, and cytogenetics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Chang YH. Myelodysplastic syndromes and overlap syndromes. Blood Res. 2021;56:S51-s64.

    Article  Google Scholar 

  2. Garcia-Manero G, Chien KS, Montalban-Bravo G. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. Am J Hematol. 2020;95:1399–420.

    Article  Google Scholar 

  3. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88.

    Article  CAS  Google Scholar 

  4. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.

    Article  CAS  Google Scholar 

  5. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364:2496–506.

    Article  CAS  Google Scholar 

  6. Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012;30:3376–82.

    Article  Google Scholar 

  7. Sotirova T, Stojanovic A, Genadieva-Stavric S, Krstevska S, Spasovski D, Balkanov T. Influence of prognostic factors on overall survival in myelodysplastic syndromes. Mater Sociomed. 2014;26:292–6.

    Article  Google Scholar 

  8. Kawabata H, Usuki K, Shindo-Ueda M, Kanda J, Tohyama K, Matsuda A, et al. Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes. Int J Hematol. 2019;110:533–42.

    Article  CAS  Google Scholar 

  9. Tennant GB, Al-Sabah AI, Burnett AK. Prognosis of myelodysplasic patients: non-parametric multiple regression analysis of populations stratified by mean corpuscular volume and marrow myeloblast number. Br J Haematol. 2002;119:87–96.

    Article  Google Scholar 

  10. Wang H, Wang X, Xu X, Lin G. Mean corpuscular volume predicts prognosis in MDS patients with abnormal karyotypes. Ann Hematol. 2010;89:671–9.

    Article  Google Scholar 

  11. Baba Y, Saito B, Shimada S, Sasaki Y, Murai S, Abe M, et al. Association of red cell distribution width with clinical outcomes in myelodysplastic syndrome. Leuk Res. 2018;67:56–9.

    Article  Google Scholar 

  12. Bejar R. Clinical and genetic predictors of prognosis in myelodysplastic syndromes. Haematologica. 2014;99:956–64.

    Article  CAS  Google Scholar 

  13. Papageorgiou SG, Kotsianidis I, Bouchla A, Symeonidis A, Galanopoulos A, Viniou NA, et al. Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes. Ther Adv Hematol. 2020;11:2040620720966121.

    Article  CAS  Google Scholar 

  14. Nazha A, Hu ZH, Wang T, Lindsley RC, Abdel-Azim H, Aljurf M, et al. A personalized prediction model for outcomes after allogeneic hematopoietic cell transplant in patients with myelodysplastic syndromes. Biol Blood Marrow Transplant. 2020;26:2139–46.

    Article  CAS  Google Scholar 

  15. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39:534–40.

    Article  Google Scholar 

  16. Dolan RD, Laird BJA, Klepstad P, Kaasa S, Horgan PG, Paulsen Ø, et al. An exploratory study examining the relationship between performance status and systemic inflammation frameworks and cytokine profiles in patients with advanced cancer. Medicine (Baltimore). 2019;98: e17019.

    Article  CAS  Google Scholar 

  17. Chidambaram V, Zhou L, Ruelas Castillo J, Kumar A, Ayeh SK, Gupte A, et al. Higher serum cholesterol levels are associated with reduced systemic inflammation and mortality during tuberculosis treatment independent of body mass index. Front Cardiovasc Med. 2021;8:696517.

    Article  CAS  Google Scholar 

  18. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004;291:451–9.

    Article  CAS  Google Scholar 

  19. Shibata H. Nutritional factors on longevity and quality of life in Japan. J Nutr Health Aging. 2001;5:97–102.

    CAS  PubMed  Google Scholar 

  20. WHO classification of tumours of haematopoietic and lymphoid tissues, International Agency for Research on Cancer (IARC), Lyon, France, 2017.

  21. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–99.

    Article  CAS  Google Scholar 

  22. Schanz J, Tuchler H, Sole F, Mallo M, Luno E, Cervera J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30:820–9.

    Article  Google Scholar 

  23. Akobeng AK. Understanding diagnostic tests 3: Receiver operating characteristic curves. Acta Paediatr. 2007;96:644–7.

    Article  Google Scholar 

  24. Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8.

    Article  CAS  Google Scholar 

  25. Ganter U, Arcone R, Toniatti C, Morrone G, Ciliberto G. Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. Embo j. 1989;8:3773–9.

    Article  CAS  Google Scholar 

  26. Andus T, Geiger T, Hirano T, Kishimoto T, Tran-Thi TA, Decker K, et al. Regulation of synthesis and secretion of major rat acute-phase proteins by recombinant human interleukin-6 (BSF-2/IL-6) in hepatocyte primary cultures. Eur J Biochem. 1988;173:287–93.

    Article  CAS  Google Scholar 

  27. Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, et al. Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol. 2012;87:1006–9.

    Article  CAS  Google Scholar 

  28. Ohno Y, Nakashima J, Nakagami Y, Gondo T, Ohori M, Hatano T, et al. Clinical implications of preoperative serum total cholesterol in patients with clear cell renal cell carcinoma. Urology. 2014;83:154–8.

    Article  Google Scholar 

  29. Gao R, Liang JH, Wang L, Zhu HY, Wu W, Cao L, et al. Low serum cholesterol levels predict inferior prognosis and improve NCCN-IPI scoring in diffuse large B cell lymphoma. Int J Cancer. 2018;143:1884–95.

    Article  CAS  Google Scholar 

  30. Tang J, Yin H, Wu JZ, Xia Y, Liang JH, Chen RZ, et al. Low serum cholesterol levels predict inferior prognosis and improve prognostic index scoring for peripheral T-cell lymphoma, unspecified. Leuk Res. 2021;103:106534.

    Article  CAS  Google Scholar 

  31. Artz AS, Logan B, Zhu X, Akpek G, Bufarull RM, Gupta V, et al. The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. Haematologica. 2016;101:1426–33.

    Article  CAS  Google Scholar 

  32. Sakamoto S, Kawabata H, Kanda J, Uchiyama T, Mizumoto C, Kondo T, et al. Differing impacts of pretransplant serum ferritin and C-reactive protein levels on the incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2013;97:109–16.

    Article  CAS  Google Scholar 

  33. Baba Y, Saito B, Shimada S, Sasaki Y, Fujiwara S, Arai N, et al. Increased serum C-reactive protein is an adverse prognostic factor in low-risk myelodysplastic syndromes. Int J Hematol. 2021;114:441–8.

    Article  CAS  Google Scholar 

  34. Arinobu Y, Kashiwado Y, Miyawaki K, Ayano M, Kimoto Y, Mitoma H, et al. Autoimmune manifestations associated with myelodysplastic syndrome predict a poor prognosis. Medicine (Baltimore). 2021;100:e25406.

    Article  CAS  Google Scholar 

  35. Komrokji RS, Kulasekararaj A, Al Ali NH, Kordasti S, Bart-Smith E, Craig BM, et al. Autoimmune diseases and myelodysplastic syndromes. Am J Hematol. 2016;91:E280–3.

    Article  Google Scholar 

  36. Zhang Q, Zhao K, Shen Q, Han Y, Gu Y, Li X, et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature. 2015;525:389–93.

    Article  CAS  Google Scholar 

  37. Busque L, Sun M, Buscarlet M, Ayachi S, Feroz Zada Y, Provost S, et al. High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential. Blood Adv. 2020;4:2430–8.

    Article  CAS  Google Scholar 

  38. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111–21.

    Article  Google Scholar 

  39. Asada S, Kitamura T. Clonal hematopoiesis and associated diseases: a review of recent findings. Cancer Sci. 2021;112:3962–71.

    Article  CAS  Google Scholar 

Download references

Funding

This work was supported by grants from Japanese Ministry of Education, Culture, Sports, Science and Technology (17591060 to Y. Masaki), Kanazawa Medical University Research Foundation (S2004-16, S2007-5 to Y. Masaki). Ministry of Health, Labour and Welfare, H29 Nanchi, Yasufumi Masaki, etc. (Nan)-General-019, Yasufumi Masaki, H27-28 Nanchi, Yasufumi Masaki, etc. (Nan)-General-002, Yasufumi Masaki,-008, Yasufumi Masaki, the Japanese Ministry of Education, Culture, Sports, Science and Technology, Grant No.17591060, Yasufumi Masaki, 15K09510, Yasufumi Masaki, Kanazawa Medical University, Grant Nos. S2004-16, Yasufumi Masaki, S2007-5, Yasufumi Masaki, Grant No. K2011-7, Yasufumi Masaki, Grant No. H2011-11, Yasufumi Masaki, AR2012-06, Yasufumi Masaki.

Author information

Authors and Affiliations

  1. Department of Hematology and Immunology, Kanazawa Medical University, Uchinada, Japan

    Hiroto Yanagisawa, Hiroshi Kawabata, Yusuke Ueda, Kotaro Arita, Haruka Iwao-Kawanami, Tomoyuki Sakai, Takafumi Kawanami, Kazunori Yamada, Shuichi Mizuta, Toshihiro Fukushima & Yasufumi Masaki

  2. Department of Hematology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan

    Hiroshi Kawabata

Authors
  1. Hiroto Yanagisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroshi Kawabata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yusuke Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kotaro Arita
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Haruka Iwao-Kawanami
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tomoyuki Sakai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takafumi Kawanami
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kazunori Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shuichi Mizuta
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Toshihiro Fukushima
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yasufumi Masaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroshi Kawabata.

Ethics declarations

Conflict-of-interest

YM received research grants from Kyowa Kirin Pharma, Astellas Pharma, Eisai Pharma, Ono Pharma, Pfizer Pharma, Asahi Kasei Pharma, MSD Pharma, Daiichi-Sankyo Pharma, Taisho Pharma, Taiho Pharma, Takeda Pharma, Chugai Pharma, Teijin Pharma, Nippon Kayaku, and Mochida Pharma, outside the submitted work. All other authors have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PPTX 86 kb)

Supplementary file2 (DOCX 18 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yanagisawa, H., Kawabata, H., Ueda, Y. et al. Prognostic impacts of serum levels of C-reactive protein, albumin, and total cholesterol in patients with myelodysplastic syndromes. Int J Hematol 116, 81–88 (2022). https://doi.org/10.1007/s12185-022-03321-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-022-03321-z

Keywords

Search

Navigation